Michael Szarek, PhD

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.